Mayne Pharma Earns Back $14.4M in Legal Costs After Court Win Over Cosette
Mayne Pharma Group has received $14,410,714.49 from Cosette Pharmaceuticals, Inc following orders made by the Supreme Court of New South Wales on 29 May 2026. The payment comprises recovery of the company’s legal costs, costs associated with its application for costs, and interest arising from proceedings over Cosette’s purported termination of a Scheme Implementation Deed signed in February 2025. The company characterises this as “another successful milestone” in litigation that produced a favourable judgment in October 2025, offsetting prior legal expenditure and supporting its balance sheet position.
Key dates and milestones:
- February 2025 – Scheme Implementation Deed signed with Cosette
- June 2025 – Proceedings commenced
- October 2025 – Judgment delivered in favour of Mayne Pharma; adverse costs order made against Cosette
- January 2026 – Cosette lodged appeal
- 29 May 2026 – Court orders issued for payment
- 2–3 June 2026 – Appeal heard in Supreme Court of New South Wales, Court of Appeal
- 5 June 2026 – Payment of $14,410,714.49 received
Legal proceedings timeline: from scheme dispute to cost recovery
The dispute between Mayne Pharma Group Limited (ASX: MYX) and Cosette Pharmaceuticals, Inc arose when Cosette purportedly terminated the Scheme Implementation Deed signed in February 2025. Mayne Pharma commenced proceedings in the Supreme Court of New South Wales in June 2025 to contest the termination.
In October 2025, the Court delivered judgment in favour of Mayne Pharma dismissing all of Cosette’s claims. The same judgment included an adverse costs order requiring Cosette to pay Mayne Pharma’s costs of the proceedings as agreed or assessed. In January 2026, Cosette lodged an appeal against the October decision.
Timeline of legal events:
- February 2025 – Scheme Implementation Deed executed
- June 2025 – Mayne Pharma commences Supreme Court proceedings
- October 2025 – Court dismisses Cosette’s claims; adverse costs order made
- January 2026 – Cosette files appeal
- 29 May 2026 – Court orders payment of costs and interest
- 5 June 2026 – Payment of $14,410,714.49 received
- 2–3 June 2026 – Appeal hearing conducted; decision reserved
The October judgment and subsequent cost recovery strengthen Mayne Pharma’s legal and negotiating position, even as the appeal outcome remains pending. Management has framed the payment as another successful milestone in the proceedings, allowing operational focus to remain on the company’s core specialty pharmaceuticals business while legal processes continue.
Fact vs. impact: what the $14.4m Cosette payment means for Mayne Pharma
The $14.4 million payment represents a recovery of past legal expenditure rather than new operating revenue. While non-recurring, it recoups costs incurred defending the company’s position and reduces the net financial burden of the litigation. The payment was received on 5 June 2026, five days after the Court issued its orders.
The appeal hearing took place on 2 and 3 June 2026 in the Supreme Court of New South Wales, Court of Appeal, with the decision now reserved. No timeline has been provided for when the appeal judgment will be delivered.
The payment improves Mayne Pharma’s cash position and potentially extends financial flexibility for growth initiatives across its dermatology, women’s health, and contract development and manufacturing services portfolios. The continuation of the appeal represents a residual overhang, but recent procedural milestones have consistently favoured Mayne Pharma.
| Event | Date | Fact | Financial Effect | Investor Impact |
|---|---|---|---|---|
| Court judgment | October 2025 | All Cosette claims dismissed | Adverse costs order secured | De-risks transaction dispute |
| Costs orders | 29 May 2026 | Court orders issued for payment of costs and interest | $14.4M payable | Recoups past legal spend |
| Payment received | 5 June 2026 | Funds transferred to Mayne Pharma | Cash position strengthened | Improves balance sheet flexibility |
| Appeal hearing | 2–3 June 2026 | Decision reserved | Outcome uncertain | Procedural overhang remains |
When big ASX news breaks, our subscribers know first
Educational: understanding legal cost recovery and appeals for ASX investors
In Australian civil litigation, when a party successfully defends a claim, the court may issue an adverse costs order requiring the unsuccessful party to pay the winner’s legal expenses. This is designed to compensate the successful party for costs incurred in defending its position.
Recovery of legal costs refers to the actual payment of these expenses by the losing party. The amount can include legal fees, disbursements, and costs associated with the application for costs itself. Interest may also accrue on these costs from the time they were incurred until payment is made, with the rate and calculation determined by court orders.
An adverse costs order is the court’s formal direction that one party must pay another’s legal expenses. In this case, the October 2025 judgment included such an order against Cosette, and the 29 May 2026 orders specified the payment amount.
When an appeal has been heard and a decision has been reserved, it means the Court of Appeal judges are deliberating and will issue their judgment at a later date. No timeline is guaranteed, and the process can take weeks or months depending on case complexity.
Key legal terms in plain English:
- Adverse costs order – Court directive requiring the losing party to pay the winner’s legal expenses
- Recovery of legal costs – Actual receipt of funds to reimburse litigation expenses
- Application for costs – Formal request to the court to quantify and order payment of legal expenses
- Decision reserved – Judges are deliberating after hearing the appeal; judgment to follow at an unspecified date
For shareholders, successful cost recovery helps protect capital during contentious transactions like a Scheme Implementation Deed. The Mayne Pharma–Cosette proceedings demonstrate how adverse costs orders can offset the financial burden of defending corporate interests. Appeal processes are normal procedural stages rather than new disputes, and investors should understand they can extend litigation timelines.
Mayne Pharma (ASX: MYX) business context and investment lens
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals that offer patients better, safer, and more accessible medicines. The Cosette legal update ties back to the broader equity story around (ASX: MYX), a business with diversified revenue streams across three key pillars.
The company is a leader in dermatology and women’s health in the United States, where it markets a portfolio of differentiated products addressing unmet patient needs. Mayne Pharma also provides contract development and manufacturing services to pharmaceutical clients worldwide, leveraging its proprietary oral drug delivery technologies. The company has a 40-year track record of innovation and success in developing new oral drug delivery systems, which have been successfully commercialised in numerous products marketed globally.
Three pillars of Mayne Pharma’s business:
- US dermatology leadership – Commercialising differentiated products targeting skin conditions
- Women’s health portfolio – Specialty products addressing unmet needs in this therapeutic area
- Global contract development and manufacturing services – Partnering with pharmaceutical clients to develop and manufacture oral formulations
Business Positioning
Mayne Pharma positions itself as a specialty pharmaceutical company with a 40-year innovation legacy in oral drug delivery systems, combining commercial success in dermatology and women’s health with global contract services capabilities.
The $14.4 million Cosette payment strengthens a business already diversified across products and services, rather than defining the investment case on its own. Investors should view the legal outcome in the context of Mayne Pharma’s long-term strategy in specialty pharmaceuticals, where the company continues to focus on commercialising novel therapies and supporting clients through its contract manufacturing platform.
The next major ASX story will hit our subscribers first
Outlook: remaining steps in the Cosette appeal and what to watch next
The outstanding matter in the legal process is the awaited decision from the Supreme Court of New South Wales, Court of Appeal following the 2–3 June 2026 hearing. The decision has been reserved, and no timing guidance for when the judgment will be delivered has been provided in the announcement.
The appeal was lodged by Cosette in January 2026 in response to the October 2025 judgment that dismissed all of Cosette’s claims and included the adverse costs order. The Court of Appeal is now considering whether the original judgment should be upheld, varied, or overturned.
The $14.4 million payment received on 5 June 2026 de-risks part of the litigation exposure by recovering costs and interest, even as the appeal continues. Investors should monitor ongoing communication channels, including ASX announcements and investor relations email alerts, for updates on the appeal outcome and any further financial impacts.
Three things for investors to watch next:
- Timing of Court of Appeal judgment – No guidance provided; decision to be issued when deliberations are complete
- Appeal outcome and financial implications – Whether the original judgment is upheld, and if any additional cost or interest outcomes arise
- Management updates – How the company communicates progress via ASX announcements and investor relations channels
To register for email alerts on Mayne Pharma announcements released to the Australian Securities Exchange, visit the company’s investor relations page at https://www.maynepharma.com/investorrelations/email-alerts/.
Ready to Explore Mayne Pharma’s Full Investment Story Beyond the Cosette Settlement?
The $14.4 million legal cost recovery strengthens Mayne Pharma’s balance sheet, but the company’s diversified specialty pharmaceuticals business—spanning US dermatology, women’s health, and global contract manufacturing—represents the core investment thesis. With a 40-year track record in oral drug delivery innovation and ongoing commercial execution across three revenue pillars, understanding the broader strategic positioning is essential.
For detailed company updates, financial reports, and ASX announcements covering Mayne Pharma’s dermatology portfolio, proprietary technologies, and growth initiatives, visit the Mayne Pharma investor centre. Stay informed on appeal outcomes and operational milestones as the specialty pharmaceuticals story continues to unfold.